1 / 39

Thoracic Surgery Innovations

Thoracic Surgery Innovations . Innovations. VATS LVRS Chemotherapy Radiotherapy PET Small Cell N2 Stents & Lasers Stapler In Oesophagogastrectomy Epidural SVC stents. VATS. Sympathectomy Pleurectomy Lobectomy Biopsy mass lung. Pneumothorax. Pleurectomy. VAT Muscle sparing

milly
Download Presentation

Thoracic Surgery Innovations

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Thoracic SurgeryInnovations

  2. Innovations • VATS • LVRS • Chemotherapy • Radiotherapy • PET • Small Cell • N2 • Stents & Lasers • Stapler In Oesophagogastrectomy • Epidural • SVC stents

  3. VATS • Sympathectomy • Pleurectomy • Lobectomy • Biopsy • mass • lung

  4. Pneumothorax

  5. Pleurectomy • VAT • Muscle sparing • Mini • Full Thoracotomy

  6. VAT Lobectomy

  7. Biopsy Lung / Pleura

  8. LVRS

  9. LVRS

  10. LVRS • Criteria • Dyspnoeic on daily activities • Age < 75 • No bullae > 5cm • Generalised emphysema with regional heterogeneity • TLC > 125% • FEV1 < 30 % • PaCO2 < 50 mmHg, PaO2 > 40 mmHg on air • No CAD or Pulmonary hypertension • Steroid < 15 mg/day

  11. LVRS • Unilateral / Bilateral • Thoracotomy / Sternotomy / VAT • Role of Physio

  12. Chemotherapy and Radiotherapy • Preoperative Neoadjuvant • Operative • Postoperative Adjuvant

  13. Chemotherapy • Numerous agents • Adjuvant • Stage II (T2N0) • ? Role in N2 disease • All oat cell • Neoadjuvant • Stage IIIA (N2) • If respond are resected • No residual tumour at surgery means prolonged survival • Experimental

  14. Radiotherapy • External beam external rays • Single / multiple beam / Fraction No • Brachy local ie intra bronchial • Interstitial directly into tumour • Intra cavity in bronchus • Adjuvant Postoperative • Neoadjuvant Preoperative

  15. Radiotherapy • Primary treatment • Stage 1 and 2 • Refuse or unfit for surgery • Failure 30 % stage 1 (T1N0), 70% stage 2 (T2N0) • 5 year survival 5 to 40% • Adjuvant for N1 / N2 • Reduces rate local recurrence • Survival unchanged • ? Role in +Ve resection margins

  16. Radiotherapy • Neoadjuvant • T3 Pancoast prior to surgery • Palliative • Symptomatic relief • Pain, haemoptysis, bronchial, SVC obstruction • Bone met pain • Brachytherapy • Local application high local dose

  17. Chemotherapy and Radiotherapy • Adjuvant • Neoadjuvant • Sequential / concurrent / alternating • Good performance status • Not standard practice • May increase risk surgery

  18. PET • 2-(fluorine-18) fluo-2-deoxy-D-glucose (18-FDG) • 18-FDG competes with glucose for facilitated transport into tumour cells and also competes with glucose for phosphorylation by hexokinase • Positive and negative predictive power

  19. Small Cell Lung Cancer

  20. Small Cell All need : Mediasteinoscopy CT head Bone scan

  21. Pre operative N2 • Young patients • Pre op chemo downstage • No evidence

  22. Stents & Lasers Malignant terminal conditions that are inoperable Benign inoperable conditions

  23. Tracheal obstruction-malignant - Pre and post Nd:Yag laser

  24. Left main bronchus extensive squamous cell carcinoma Metal stent in left main

  25. Stapler In Oesophagogastrectomy

  26. Epidural • Pain • Poor PFTs • Cardiac history • Contraindications • Low risk • On anticoagulants • Consent • Anatomical • Infective

  27. SVC Stents

  28. Any Questions ?

  29. Next Week2nd MarchInotropesITU seminar room

More Related